Search company, investor...

Seredigm

Founded Year

2006

Stage

Series A | Alive

Total Raised

$2.5M

Valuation

$0000 

Last Raised

$2.5M | 17 yrs ago

About Seredigm

Seredigm is a Healthcare/Pharmaceuticals / Drugs company based in Washington. Seredigm's investors include MPM Capital, Versant Ventures, Alexandria Real Estate Equities, Amgen Ventures, OVP Venture Partners and Arch Venture Partners.

Headquarters Location

1616 Eastlake Avenue East 200

Seattle, Washington, 98102,

United States

Missing: Seredigm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Seredigm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Seredigm Frequently Asked Questions (FAQ)

  • When was Seredigm founded?

    Seredigm was founded in 2006.

  • Where is Seredigm's headquarters?

    Seredigm's headquarters is located at 1616 Eastlake Avenue East 200, Seattle.

  • What is Seredigm's latest funding round?

    Seredigm's latest funding round is Series A.

  • How much did Seredigm raise?

    Seredigm raised a total of $2.5M.

  • Who are the investors of Seredigm?

    Investors of Seredigm include OVP Venture Partners, Amgen Ventures, Alexandria Venture Investments, MPM Capital, ARCH Venture Partners and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.